In terminal-sterilised veterinary injectables, sodium hydroxide and potassium hydroxide are introduced as dilute volumetric solutions rather than dry solids because the heat of dissolution of solid hydroxide in aqueous media creates localised hot spots that can degrade thermolabile active substances. Although the two hydroxides are listed as veterinary-grade raw materials in this application class, they function as pH-adjusting and salt-forming excipients, not as the therapeutic entity. Their acceptability in parenteral processing is governed by the compendial monographs for total alkali, carbonate, insoluble matter, and clarity of solution. A typical bulk adjustment operation uses a 1 N sodium hydroxide stock solution metered into a 316L stainless steel jacketed vessel equipped with bottom-mounted magnetic-drive agitation and an in-line glass electrode calibrated at pH 4.01, pH 7.00, and pH 10.01 per USP <791> and Ph. Eur. 2.2.3. Endpoint control is set at the target pH ± 0.05 units; a deviation above 0.10 units normally requires back-titration with dilute acid, which increases ionic strength and may shift tonicity outside the registered formula.

Selection between sodium hydroxide and potassium hydroxide is governed by target electrolyte composition. Potassium hydroxide is used when the approved veterinary dossier specifies sodium restriction, or when the active substance requires the potassium salt for differential solubility. For weak-acid actives, the neutralisation reaction converts the free acid to its alkali salt; the resulting salt usually displays higher aqueous solubility but may exhibit reduced chemical stability if the molecule contains ester, amide, or β-lactam groups. Hydrolysis rate constants increase as pH moves above 8.0, and the choice between 0.1 N and 1 N alkali is a process-critical variable. A 0.1 N solution adds 10 times the volume to deliver the same equivalents; this reduces local pH overshoot at the addition nozzle but can exceed the allowable final batch volume. The hydroxide is therefore added slowly through a peristaltic pump, often at a rate not exceeding 0.5 L/min per 500 L bulk, while pH is recorded at 30-second intervals.

After pH adjustment, the bulk is filtered through a 0.22 µm sterilising-grade membrane. Membrane compatibility must be confirmed by filter validation because high-pH process fluids can alter zeta potential and extractables from certain PVDF supports; PTFE or polyethersulfone membranes with documented pH 1–14 compatibility are often specified. The sterile-filtered solution is filled into Type I borosilicate glass vials per USP <660>. Sustained pH above 8.0 in glass containers raises the risk of surface leaching and delamination, evaluated by USP <1660>. Terminal sterilisation at 121°C for 15 minutes can produce pH drift of 0.1–0.3 units in unbuffered or weakly buffered systems due to hydrolysis of excipient esters and glass surface reactions. The manufacturing record therefore includes pre-sterilisation pH sampled from three vessel depths and post-sterilisation pH from statistically selected vials. Acceptance criteria for endotoxins and particulate matter are assessed after pH adjustment; USP <85> and USP <788> remain the relevant parenteral control chapters even when the formulation pH is alkaline.

What Restricts Hydroxide Use in Oral Drench and Drinking-Water Solutions Beyond pH Correction?

Oral veterinary solutions and drenches are buffered less aggressively than injectables, and most of their formulation work with sodium hydroxide or potassium hydroxide is directed toward converting weakly acidic active substances into water-soluble salts. The reaction is performed in a stainless steel or glass-lined vessel with overhead stirring; a 1 N alkali solution is added to a slurry of the active in purified water until a clear solution is obtained, generally at pH 4.5–7.5 because oral ingesta and palatability limit higher alkalinity. Continuous pH measurement follows USP <791>, with a two-point calibration bracketing the expected range. Single-point calibration between 7.00 and 10.01 is inadequate when the target is below 6.0. Potassium hydroxide is selected where potassium salt formation improves dissolution or where sodium intake is a stated clinical constraint in the target species, for example in some poultry and ruminant electrolyte drenches. Solid potassium hydroxide is not recommended for direct charge in this operation because its heat of solution and hygroscopicity produce hard lumps and localised boiling at the addition point. Alkali is added at a rate that maintains the bulk liquid below 30°C when the active is thermolabile; a cooling jacket with chilled water at 10–15°C is often necessary for batches above 200 L.

Uncontrolled overtitration into the pH 9–11 range accelerates saponification of ester-containing actives and may generate a soapy taste. Oral solutions for monogastric animals usually reject pH above 8.0 because of gastric acid buffering and palatability; drenches for ruminants may tolerate up to pH 8.5 if administered by balling gun, but this is species-specific and must be justified in the marketing authorisation. Carbon dioxide absorption from ambient air lowers the effective hydroxide concentration and forms carbonate; bulk solution should be blanketed with nitrogen and stored in sealed HDPE or polypropylene containers. Glass containers should be avoided for concentrated alkali stock solutions because they can seize glass stoppers and etch the inner surface over time. Paraben preservatives undergo hydrolysis above pH 8.0, reducing oral solution shelf life; this limitation is often documented in stability batches as a pH-dependent degradation rate rather than a single failure threshold. Standard 1 N and 0.1 N sodium hydroxide solutions are prepared and standardised against potassium biphthalate; titre is not valid beyond 30 days unless protected from carbon dioxide and re-verified.

Wet granulation of veterinary tablets introduces the hydroxide source as a component of the granulating liquid, usually at concentrations below 0.5 N because higher normality damages starch-based binders and accelerates hydrolysis of disintegrants such as croscarmellose sodium. Two process routes are used. In the first route, sodium hydroxide pre-neutralizes a polymeric binder or acidic filler to reduce binding variation between batches; in the second route, it converts a free-acid active substance to its sodium salt in situ, eliminating a separate salt formation step. The granulating liquid is sprayed from a top-spray nozzle onto a moving powder bed in a fluid-bed granulator with inlet air temperature controlled to 50–65°C and product temperature between 28°C and 38°C. Spray rate is adjusted so that bed relative humidity remains below 60% to prevent localised overwetting. Alkaline granulating fluids can cause viscosity rise in starch binder systems; when pH exceeds 9.0, gelatinised starch may become more sticky, increasing impeller torque and leading to hard, poorly friable granules. Batch records therefore track granulator amperage or torque as an indirect plasticity signal. After drying, finished granules are assessed for loss on drying at 105°C until the result is below 2.0% w/w, and particle size distribution is measured by sieve analysis. A narrow granule size between 125 µm and 850 µm is usually specified for tablet compression; high alkali content can increase hygroscopicity and sieving-induced caking if stored above 50% RH.

Compression is conducted on a rotary tablet press with pre-compression force between 4 kN and 8 kN and main compression force adjusted to produce tablet hardness of 8–15 kp for a veterinary oral tablet. The exact force depends on tablet shape and tooling; no universal hardness value exists. Dissolution testing is performed per USP <711> using apparatus 2 at 50 rpm and the pH stated in the dossier, commonly pH 6.8 phosphate buffer or pH 4.5 acetate buffer. Tablets containing alkali-generated sodium salts often display rapid disintegration below pH 5.0 but slower release as the pH rises because the ionised species solubility changes. Sodium hydroxide itself is not directly compressible and is never added as a dry solid to the final blend; any residual sodium from the neutralised active can increase tablet hygroscopicity and shorten shelf life if the moisture-barrier packaging is inadequate. Powder contact surfaces should be 316L stainless steel or higher; alkaline residues on non-stainless tooling can cause corrosion and cross-contamination.

When Potassium Hydroxide Replaces Sodium Hydroxide in Capsule Fill pH Control

Capsule fill formulations that require pH adjustment above the point of complete dissolution are usually liquid or semi-solid vehicles filled into hard gelatin or hypromellose shells. The hydroxide is added to the fill vehicle in a jacketed glass-lined vessel, and potassium hydroxide is chosen over sodium hydroxide when the target active salt is potassium, when sodium intake is limited, or when the fill matrix is a high-molecular-weight polyethylene glycol in which the potassium salt of an acidic active exhibits lower viscosity than the sodium equivalent. This viscosity difference is molecule-specific; published data for a given veterinary capsule fill is often limited, so laboratory-scale viscosity curves must be generated during preformulation rather than assumed. The fill vehicle is adjusted to a pH that balances active solubility against shell compatibility. Hard gelatin shells are susceptible to crosslinking and delayed disintegration when the fill pH exceeds 9.0; gelatin shell moisture content at 13–16% w/w accelerates the reaction with residual aldehydes, and the resulting pellicle may fail disintegration per USP <701>. Hypromellose shells tolerate a wider pH range but are not immune to high alkalinity. Standard fill pH for gelatin capsules is therefore maintained between 6.0 and 8.5 unless a specific shell coating or sealant is validated.

Potentiometric pH measurement of non-aqueous or glycol-based fill matrices requires a pH electrode with an electrolyte compatible with the solvent; direct aqueous pH readings are not representative. Filling on a capsule machine with volumetric dosing units requires viscosity below approximately 1 000 mPa·s at 25°C; addition of hydroxide can increase viscosity if it creates salt bridges or saponifies excipient esters. Cleaning after alkaline fills requires a rinse with purified water followed by dilute acid to neutralise residue on stainless steel contact surfaces; 21 CFR 211.67(a) requires documented equipment cleaning procedures and verification. Potassium hydroxide is more hygroscopic than sodium hydroxide, so open storage of solid KOH in the dispensing room can increase carbonate formation and variation in stock solution normality. For this reason, KOH-based capsule fill processes are typically controlled by liquid dispensing from sealed drums rather than manual weighing of pellets.

Spray-dried oral powders intended for drinking-water administration use sodium hydroxide sparingly to convert acid actives to their sodium salts before drying; the drying process then removes water and leaves the salt distributed in a water-dispersible matrix. The aqueous feed is prepared at 40–50°C in a stainless mixing vessel, and pH is adjusted with 0.1 N sodium hydroxide to a target between 6.5 and 7.5. The feed is transferred through a 100–150 µm in-line filter to remove undissolved floccs and then atomised in a co-current spray dryer with inlet air temperature 160–180°C and outlet air temperature 70–85°C. For heat-sensitive molecules, the lower inlet temperature is selected even though it reduces evaporation capacity. The resulting powder is assessed for moisture content by Karl Fischer titration; typical specifications are below 2.0% w/w. Residual alkalinity is determined by reconstituting a 10.0 g sample in 100.0 mL carbon dioxide-free water and measuring pH; a shift of more than 0.5 pH units from the final drinking-water concentration indicates incomplete neutralisation or carbonate contamination.

The powder should be protected from ambient humidity because sodium salts formed by hydroxide neutralisation are frequently hygroscopic; packaging in aluminium foil laminate with desiccant is specified for moisture-sensitive veterinary powders. Feed pH above 7.5 during spray drying can increase residual sodium carbonate and produce caked product below 60% RH. Bulk density, tap density, and compressibility are measured according to USP <616>; high residual alkalinity increases particle aggregation in some formulations and can reduce flow through rotary filling equipment. Direct addition of solid sodium hydroxide to a powder blender is avoided because of deliquescence and poor distribution; the hydroxide is introduced only as a solution to the feed slurry. This also limits the formation of hot spots that can discolour carbohydrate-based carriers through alkaline degradation.

Granule and Extrusion-Spheronization Alkalinity Limits in Veterinary Oral Granules

Granules for oral administration differ from tablet granulations because the final granule is the dosage unit, not an intermediate for compression. Sodium hydroxide or potassium hydroxide is used in the wet mass stage to convert an acidic active to its salt or to pre-neutralise an acidic binder such as a carbomer. The wet mass is passed through an oscillating granulator or extruder-spheronizer; alkaline wet mass can increase extruder torque if the amount of hydroxide exceeds the point of complete neutralisation and begins to plasticise polymeric binders. Extrusion speed and screen temperature are monitored because residual sodium hydroxide accelerates corrosion of non-stainless steel parts; product-contact surfaces should be 316L stainless steel or higher. The spheronization step generates heat and fines; high-pH granule surfaces may increase fines adhesion and reduce sphericity if the water content is too high. In-process control therefore includes moisture content by loss on drying at 105°C until below 2.5% w/w for oral granules, and pH of a 10% aqueous dispersion.

Final granules are dried in a fluid-bed dryer with inlet air between 55°C and 70°C and then sized over a 500 µm screen. Alkalinity above pH 8.5 in the reconstituted granule suspension can irritate oral mucosa and is normally rejected for oral veterinary use. Dissolution testing for granules is conducted per USP <711> or the relevant veterinary dossier method, typically with apparatus 2 at 50 rpm or apparatus 3 for modified-release beads. Sodium hydroxide residues beyond the neutralisation equivalent can raise the pH of the dissolution medium above the intended sink condition, producing non-robust release data. This is quantified by generating release profiles in media adjusted to pH 1.2, pH 4.5, and pH 6.8; a pronounced pH-dependent release shift signals incomplete salt formation or excess free alkali.

Medicated Premix Carrier pH Correction Accelerates Vitamin Degradation

Medicated premixes present a different constraint profile because the hydroxide is added to adjust acidic carrier components rather than to dissolve an active. Typical carriers such as corn cob, rice hulls, calcium carbonate, or lactose can deviate in pH depending on moisture and organic acid content; the premix formulation may include a low-concentration hydroxide solution during carrier conditioning to bring the final blended premix pH into the range of 5.5–7.5. The solution is applied via a ribbon mixer spray bar at 0.5–2.0% w/w liquid addition, depending on carrier water-holding capacity; carrier moisture after drying should remain below 12% w/w to prevent mould growth. Excessive alkalinity in a vitamin-containing premix accelerates degradation of retinol, cholecalciferol, and riboflavin; vitamin A degradation kinetics are more favourable below pH 7.0, and high pH combined with trace minerals such as copper and iron promotes oxidative pathways via Fenton-type reactions. For this reason, sodium hydroxide treatment of a mineral-vitamin premix is often limited to neutralisation of specific acidic carriers before blending with sensitive vitamins, or omitted entirely in favour of calcium carbonate blending.

The final premix pH is measured in a 10% aqueous dispersion; no fully harmonised pH monograph exists for all premix types, so the specification must be justified in the dossier. Mixing vessels for liquid hydroxide addition to carriers are typically 316L stainless steel or high-density polyethylene; carbon steel surfaces are unsuitable because alkaline solutions can cause stress corrosion cracking under repeated exposure. Homogeneity of hydroxide distribution is assessed by collecting 10–15 thief samples from the ribbon mixer and testing pH and assay of the active; the acceptance criteria are defined by the approved variance, often requiring a relative standard deviation below 5.0% for content uniformity. Premixes containing alkali-generated sodium salts can absorb moisture during storage; multilayer paper sacks with polyethylene liners and desiccant are used for products with demonstrated hygroscopicity above 50% RH. The operational boundary is clear: hydroxide use in a premix must not create a carrier pH above 7.5 when oxidation-sensitive vitamins are present, because the resulting degradation is concentration-dependent and accelerated by metal ions.